Long Non-Coding RNA OIP5-AS1 Contributes to Gallbladder Cancer Cell Invasion and Migration by miR-143-3p Suppression.

OIP5-AS1 gallbladder cancer invasion miR-143-3p migration proliferation

Journal

Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700

Informations de publication

Date de publication:
2020
Historique:
received: 25 08 2020
accepted: 26 11 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

This study was designed to investigate the effect of long non-coding RNA (lncRNA) OIP5-AS1 on cell migration and invasion of gallbladder cancer (GBC) and its specific mechanism. The expressions of lncRNA OIP5-AS1 and OIP5-AS1 was highly expressed and LncRNA OIP5-AS1 accelerates the progression of GBC by suppressing miR-143-3p.

Identifiants

pubmed: 33364844
doi: 10.2147/CMAR.S278719
pii: 278719
pmc: PMC7751711
doi:

Types de publication

Journal Article

Langues

eng

Pagination

12983-12992

Informations de copyright

© 2020 Li et al.

Déclaration de conflit d'intérêts

The authors declare they have no conflicts of interest.

Références

Biomed Pharmacother. 2018 May;101:14-23
pubmed: 29475118
Onco Targets Ther. 2019 Oct 01;12:8047-8053
pubmed: 31632058
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8179-8185
pubmed: 30556856
Theranostics. 2018 Jan 1;8(4):1084-1105
pubmed: 29464001
Oncotarget. 2017 Jul 25;8(30):49409-49420
pubmed: 28472763
Am J Transl Res. 2018 Mar 15;10(3):866-874
pubmed: 29636876
J Cell Biochem. 2019 Jan;120(1):907-916
pubmed: 30188591
Thorac Cancer. 2018 Aug;9(8):939-949
pubmed: 29897167
Oncotarget. 2017 Apr 25;8(17):28711-28724
pubmed: 28404925
Surg Clin North Am. 2019 Apr;99(2):337-355
pubmed: 30846038
J Physiol Biochem. 2020 May;76(2):301-315
pubmed: 32157498
Front Cardiovasc Med. 2019 May 16;6:56
pubmed: 31157238
Onco Targets Ther. 2020 Mar 20;13:2357-2367
pubmed: 32256086
Biomed Pharmacother. 2018 Oct;106:1441-1447
pubmed: 30119217
Tumour Biol. 2016 Sep;37(9):12867-12875
pubmed: 27449039
Biosci Rep. 2020 Apr 30;40(4):
pubmed: 32270853
Front Pharmacol. 2019 Apr 24;10:449
pubmed: 31068824
Cell Death Dis. 2018 Feb 7;9(2):182
pubmed: 29416013
Oncotarget. 2017 Jul 18;8(29):47957-47968
pubmed: 28624787
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):353-361
pubmed: 31899963
Biomed Pharmacother. 2019 Oct;118:109259
pubmed: 31369989
Cell Physiol Biochem. 2017;42(5):2078-2092
pubmed: 28803245
Mutat Res. 2018 Oct - Dec;778:61-71
pubmed: 30454684
Naunyn Schmiedebergs Arch Pharmacol. 2020 Nov;393(11):2177-2184
pubmed: 32009213
EMBO Rep. 2017 Oct;18(10):1837-1853
pubmed: 28887321
Mol Cancer. 2019 Nov 21;18(1):167
pubmed: 31752906
J Cell Physiol. 2019 Apr;234(4):5264-5275
pubmed: 30341904
J Gastrointest Cancer. 2014 Sep;45(3):245-55
pubmed: 24652122

Auteurs

Jing Li (J)

Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, People's Republic of China.

Hui Zhang (H)

Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, People's Republic of China.

Hongwu Luo (H)

Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, People's Republic of China.

Classifications MeSH